tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Franke EK and Luban J Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. 1996 Virology pmid:8806510
Spencer DM et al. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. 1996 Curr. Biol. pmid:8805308
Zhang Q et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8799169
Brunke M et al. Luciferase assembly after transport into mammalian microsomes involves molecular chaperones and peptidyl-prolyl cis/trans-isomerases. 1996 J. Biol. Chem. pmid:8798557
Platz KP et al. Management of acute steroid-resistant rejection after liver transplantation. 1996 World J Surg pmid:8798364
Buckle GJ et al. HTLV-I-induced T-cell activation. 1996 J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. pmid:8797712
Shapiro R et al. The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. 1995 Clin Transpl pmid:8794266
Abu-Elmagd K et al. The current status of hepatic transplantation at the University of Pittsburgh. 1995 Clin Transpl pmid:8794262
Ikebe S et al. Immunosuppressive effect of tacrolimus (FK-506). Bone xenografts in rabbits. 1996 Acta Orthop Scand pmid:8792745
Venkataramanan R et al. Clinical pharmacokinetics of tacrolimus. 1995 Clin Pharmacokinet pmid:8787947
Gonschior AK et al. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. 1996 Clin. Chem. pmid:8787699
Michel G et al. Antioncogene P53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506). 1996 Biochem. Pharmacol. pmid:8787547
Dumont FJ et al. Mixed agonist/antagonist activity of an FK-506-related immunosuppressant: biological and biochemical characterization. 1996 J. Pharmacol. Exp. Ther. pmid:8786538
Wagenknecht T et al. Cryoelectron microscopy resolves FK506-binding protein sites on the skeletal muscle ryanodine receptor. 1996 Biophys. J. pmid:8785329
Silva ND and Prendergast FG Tryptophan dynamics of the FK506 binding protein: time-resolved fluorescence and simulations. 1996 Biophys. J. pmid:8785272
Steiner JP et al. Immunophilin regulation of neurotransmitter release. 1996 Mol. Med. pmid:8784785
Singh N and Yu VL Prophylaxis for cytomegalovirus disease after liver transplant. 1996 Clin. Infect. Dis. pmid:8783744
Craescu CT et al. Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution. 1996 Biochemistry pmid:8780506
Lufft V et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. 1996 Transplantation pmid:8779695
Newell KA et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. 1996 Transplantation pmid:8779685
Schwarz A [Drug-induced kidney damage]. 1996 Z Arztl Fortbild (Jena) pmid:8779233
Dmitrewski J et al. Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. 1996 J. Hepatol. pmid:8778189
Mugiya S et al. Renal blood flow and serotonin metabolism in tacrolimus treated rats. 1996 Int. J. Urol. pmid:8776615
Ichikawa Y et al. Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. 1996 Int. J. Urol. pmid:8776613
Randhawa PS et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. 1996 Am. J. Surg. Pathol. pmid:8772784
Tanaka M et al. Reduction of immunosuppressive agents after living related donor liver transplantation. 1996 Transplant. Proc. pmid:8769268
Melter M et al. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients. 1996 Transplant. Proc. pmid:8769224
Baruch Y et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. 1996 Transplant. Proc. pmid:8769215
Jordan ML et al. Tacrolimus rescue therapy for renal transplant rejection. 1996 Transplant. Proc. pmid:8769174
Masaki Y et al. Microchimerism and rat small bowel transplantation combined with donor-type bone marrow cells. 1996 Transplant. Proc. pmid:8769154
Becker G et al. Diltiazem minimizes tubular damage due to FK506-mediated nephrotoxicity following ischemia and reperfusion in rats. 1996 Transpl. Immunol. pmid:8762016
Tomono M et al. Calcineurin is essential for DNA synthesis in Swiss 3T3 fibroblasts. 1996 Biochem. J. pmid:8760349
Rokaw MD et al. FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells. 1996 Am. J. Physiol. pmid:8760046
Gusev AI et al. A quantitative study of in vitro hepatic metabolism of tacrolimus (FK506) using secondary ion and matrix-assisted laser desorption/ionization mass spectrometry. 1996 Rapid Commun. Mass Spectrom. pmid:8759330
Brunner T et al. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. 1996 Int. Immunol. pmid:8757947
Venkataraman L et al. Differential regulation of c-Rel translocation in activated B and T cells. 1996 J. Immunol. pmid:8757620
Sperr WR et al. Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. 1996 J. Allergy Clin. Immunol. pmid:8757216
Yamashita M et al. Non-T cell-derived IL-4 plays an important role in IgE production induced by antigen resensitization and is resistant to FK506. 1996 J. Immunol. pmid:8752921
Motamedi H et al. Characterization of methyltransferase and hydroxylase genes involved in the biosynthesis of the immunosuppressants FK506 and FK520. 1996 J. Bacteriol. pmid:8752344
Ho SN et al. Dimeric ligands define a role for transcriptional activation domains in reinitiation. 1996 Nature pmid:8752278
Sunyecz JA et al. Lymphoproliferative disorder involving the cervix in a patient being treated with FK-506. 1996 Gynecol. Oncol. pmid:8751565
Ichinari H et al. Effects of portal venous inoculation with donor splenocytes on lung allograft survival in dogs. 1996 J. Thorac. Cardiovasc. Surg. pmid:8751494
Seifeldin R Drug interactions in transplantation. 1995 Nov-Dec Clin Ther pmid:8750397
Miranker A and Karplus M An automated method for dynamic ligand design. 1995 Proteins pmid:8749844
Jonas S et al. Conversion to tacrolimus after liver transplantation. 1996 Transpl. Int. pmid:8748407
Sheppard KE Cyclosporin A and FK506 are potent activators of proopiomelanocortin-derived peptide secretion without affecting corticotrope glucocorticoid receptor function. 1995 J. Neuroendocrinol. pmid:8748119
Nowaczyk M et al. 2-Chlorodeoxyadenosine: lack of synergism with cyclosporine A and tacrolimus (FK 506). 1995 Arch. Immunol. Ther. Exp. (Warsz.) pmid:8744655
Cooley HM et al. Resolution of pyoderma gangrenosum using tacolimus (FK-506) 1996 Aust N Z J Med pmid:8744629
Thompson PA and Mosley CA Tacrolimus-phenytoin interaction. 1996 Ann Pharmacother pmid:8740340
Ockenfels HM et al. Inhibition of T cell cAMP formation by cyclosporin A and FK506. 1996 Naunyn Schmiedebergs Arch. Pharmacol. pmid:8740144
Alak AM and Lizak PP Quality assurance procedure for monitoring tacrolimus (FK506) concentrations in whole blood by IMx assay. 1996 Ther Drug Monit pmid:8738766
Herget S et al. Initial experience with tacrolimus rescue therapy in OKT3 resistant rejection. 1996 Clin. Nephrol. pmid:8738671
Hohage H et al. Influence of cyclosporine A and FK506 on 24 h blood pressure monitoring in kidney transplant recipients. 1996 Clin. Nephrol. pmid:8738668
Wagner K et al. Experimental and clinical experience with the use of tacrolimus (FK506) in kidney transplantation. 1996 Clin. Nephrol. pmid:8738666
Okada K et al. Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. 1996 Ophthalmologica pmid:8738464
Herzog D et al. Combined bowel-liver transplantation in an infant with microvillous inclusion disease. 1996 J. Pediatr. Gastroenterol. Nutr. pmid:8732907
Asante-Korang A et al. Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects. 1996 J. Heart Lung Transplant. pmid:8732602
Saada V et al. Comparative evaluation of in vitro and in vivo immunosuppressive potential of cyclosporin G with cyclosporin A and FK-506. 1996 Int. J. Immunopharmacol. pmid:8732436
Lampen A et al. Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. 1996 Br. J. Pharmacol. pmid:8732283
Soubrane O and Houssin D [Liver transplantation. Current aspects]. 1996 Presse Med pmid:8728904
Hashino S et al. Antitumor effect in cyclosporine A- or FK506-treated mice after syngeneic bone marrow transplantation. 1996 Leuk. Lymphoma pmid:8726416
Fealy MJ and Press BH Pinpointing the moment of allograft rejection. 1996 J Hand Surg Am pmid:8724501
Yu C et al. Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. 1996 Bone Marrow Transplant. pmid:8722370
Alak AM and Lizak P Stability of FK506 in blood samples. 1996 Ther Drug Monit pmid:8721287
Shultz SL and Meriney DK Cyclosporine and tacrolimus: a comparison of immunosuppressants used for liver transplantation. 1996 Jul-Aug Dimens Crit Care Nurs pmid:8717641
Frezza EE et al. Small bowel transplantation: current progress and clinical application. 1996 Mar-Apr Hepatogastroenterology pmid:8714229
Christophers E Psoriasis: mechanisms and entry points for possible therapeutic interventions. 1996 Australas. J. Dermatol. pmid:8713012
Tokime T et al. Neuroprotective effect of FK506, an immunosuppressant, on transient global ischemia in gerbil. 1996 Neurosci. Lett. pmid:8710192
Hartley AD et al. cAMP inhibits bud growth in a yeast strain compromised for Ca2+ influx into the Golgi. 1996 Mol. Gen. Genet. pmid:8709962
Rahfeld JU et al. Isolation and amino acid sequence of a new 22-kDa FKBP-like peptidyl-prolyl cis/trans-isomerase of Escherichia coli. Similarity to Mip-like proteins of pathogenic bacteria. 1996 J. Biol. Chem. pmid:8703024
Okadome T et al. Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. 1996 J. Biol. Chem. pmid:8702959
Shih M and Malbon CC Protein kinase C deficiency blocks recovery from agonist-induced desensitization. 1996 J. Biol. Chem. pmid:8702931
Timerman AP et al. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. 1996 J. Biol. Chem. pmid:8702774
Raufman JP et al. Calcineurin mediates calcium-induced potentiation of adenylyl cyclase activity in dispersed chief cells from guinea pig stomach. Further evidence for cross-talk between signal transduction pathways that regulate pepsinogen secretion. 1996 J. Biol. Chem. pmid:8702699
Tyedmers J et al. Efficient folding of firefly luciferase after transport into mammalian microsomes in the absence of luminal chaperones and folding catalysts. 1996 J. Biol. Chem. pmid:8702642
Hemenway CS and Heitman J Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. 1996 J. Biol. Chem. pmid:8702500
Mach-Pascual S et al. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. 1996 Am. J. Hematol. pmid:8701950
Bousvaros A et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). 1996 Gastroenterology pmid:8698205
Shaw LM et al. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. 1996 Clin. Chem. pmid:8697605
Fung JJ et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. 1996 J. Am. Coll. Surg. pmid:8696542
Bashuda H et al. Induction of persistent allograft tolerance in the rat by combined treatment with anti-leukocyte function-associated antigen-1 and anti-intercellular adhesion molecule-1 monoclonal antibodies, donor-specific transfusion, and FK506. 1996 Transplantation pmid:8693525
Luan S et al. Molecular characterization of a FKBP-type immunophilin from higher plants. 1996 Proc. Natl. Acad. Sci. U.S.A. pmid:8692927
Lampen A et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. 1995 Drug Metab. Dispos. pmid:8689938
Huntress JD and Papadakos PJ The role of calcium-channel antagonists in solid organ transplantation. 1996 New Horiz pmid:8689268
Tsugita M et al. Tacrolimus pretreatment attenuates preexisting xenospecific immunity and abrogates hyperacute rejection in a presensitized hamster to rat liver transplant model. 1996 Transplantation pmid:8685952
Pirenne J et al. Combined transplantation of small and large bowel. FK506 versus cyclosporine A in a porcine model. 1996 Transplantation pmid:8685944
Pullicino P et al. Posterior leucoencephalopathy syndrome. 1996 Lancet pmid:8684128
Halloran PF Molecular mechanisms of new immunosuppressants. 1996 Clin Transplant pmid:8680047
Adams DH and Liu Q FK506 inhibits human lymphocyte migration and the production of lymphocyte chemotactic factors in liver allograft recipients. 1996 Hepatology pmid:8675167
Mattila PS The actions of cyclosporin A and FK506 on T-lymphocyte activation. 1996 Biochem. Soc. Trans. pmid:8674715
Hall MN The TOR signalling pathway and growth control in yeast. 1996 Biochem. Soc. Trans. pmid:8674674
Schmaldienst S and Horl WH Bacterial infections during immunosuppression - immunosuppressive agents interfere not only with immune response, but also with polymorphonuclear cell function. 1996 Nephrol. Dial. Transplant. pmid:8672015
Kay JE Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. 1996 Biochem. J. pmid:8670043
Uchikoshi F et al. Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. 1996 Transplantation pmid:8669109
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Tokunaga Y and Alak AM FK506 (tacrolimus) and its immunoreactive metabolites in whole blood of liver transplant patients and subjects with mild hepatic dysfunction. 1996 Pharm. Res. pmid:8668663
Kralli A and Yamamoto KR An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. 1996 J. Biol. Chem. pmid:8663352
Owens-Grillo JK et al. A model of protein targeting mediated by immunophilins and other proteins that bind to hsp90 via tetratricopeptide repeat domains. 1996 J. Biol. Chem. pmid:8662874
Schaefer A et al. Ca2+/calmodulin-dependent and -independent down-regulation of c-myb mRNA levels in erythropoietin-responsive murine erythroleukemia cells. The role of calcineurin. 1996 J. Biol. Chem. pmid:8662717
Kanzler S et al. Complete reversal of FK 506 induced diabetes in a liver transplant recipient by change of immunosuppression to cyclosporine A. 1996 Z Gastroenterol pmid:8659188